J. B. TandanHeechoul OhrrYoung Mo SohnSutee YoksanMin JiChung Mo NamScott B. HalsteadCouncil for Technical Education and Vocational TrainingYonsei University College of MedicineMahidol UniversityGlovax Co., Ltd.Uniformed Services University of the Health Sciences2018-08-242018-08-242007-06-28Vaccine. Vol.25, No.27 (2007), 5041-50450264410X2-s2.0-34250028171https://repository.li.mahidol.ac.th/handle/20.500.14594/24536In July 1999, a single dose of live-attenuated SA 14-14-2 Japanese encephalitis (JE) vaccine was administered to children living in the Bardiya, Banke and Kailali districts of Nepal. In 2004, the original vaccinated population experienced a fifth seasonal exposure to JE. We performed a case-control study comparing the prevalence of the administration of vaccine in patients with JE hospitalized in the Bardiya and Bheri Zonal hospitals and in age-sex matched controls resident in the Bardiya district. Among the 219 village controls, 114 had been vaccinated (52.1%) while only one of 20 JE cases had received live-attenuated JE vaccine. Five years after administration of a single dose, SA 14-14-2 provided a protective efficacy of 96.2% (CI 73.1-99.9%). © 2007 Elsevier Ltd. All rights reserved.Mahidol UniversityImmunology and MicrobiologyMedicineVeterinaryArticleSCOPUS10.1016/j.vaccine.2007.04.052